A blinded randomised controlled trial to determine the effect of enteric coating on enzyme treatment for canine exocrine pancreatic insufficiency

BMC Veterinary Research

Alexander J German²  Peter Graham¹  Daniel J Batchelor²  Peter J Cripps²  Peter-John M Noble²  Aran Mas² 

[1] Nationwide Laboratories Lancefield House, 23 Mains Lane, Poulton-le-Fylde, United Kingdom;School of Veterinary Science, University of Liverpool, Neston, United Kingdom

关键词: Trypsin;    Lipase;    Diarrhoea;    Malabsorption;    Pancreas;    Dog;   

Others  :  1119760
DOI  :  10.1186/1746-6148-8-127

 received in 2012-04-02, accepted in 2012-07-28,  发布年份 2012

【 摘 要 】

Background

Enzyme treatment is the mainstay for management of exocrine pancreatic insufficiency (EPI) in dogs. ‘Enteric-coated’ preparations have been developed to protect the enzyme from degradation in the stomach, but their efficacy has not been critically evaluated. The hypothesis of the current study was that enteric coating would have no effect on the efficacy of pancreatic enzyme treatment for dogs with EPI.

Thirty-eight client-owned dogs with naturally occurring EPI were included in this multicentre, blinded, randomised controlled trial. Dogs received either an enteric-coated enzyme preparation (test treatment) or an identical preparation without the enteric coating (control treatment) over a period of 56 days.

Results

There were no significant differences in either signalment or cobalamin status (where cobalamin deficient or not) between the dogs on the test and control treatments. Body weight and body condition score increased in both groups during the trial (P<0.001) but the magnitude of increase was greater for the test treatment compared with the control treatment (P<0.001). By day 56, mean body weight increase was 17% (95% confidence interval 11-23%) in the test treatment group and 9% (95% confidence interval 4-15%) in the control treatment group. The dose of enzyme required increased over time (P<0.001) but there was no significant difference between treatments at any time point (P=0.225). Clinical disease severity score decreased over time for both groups (P=0.011) and no difference was noted between groups (P=0.869). No significant adverse effects were reported, for either treatment, for the duration of the trial.

Conclusions

Enteric coating a pancreatic enzyme treatment improves response in canine EPI.

【 授权许可】

   
2012 Mas et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Westermarck E, Wiberg M, Steiner J, Williams DA: Exocrine pancreatic insufficiency in dogs and cats. In Textbook of veterinary internal medicine. 6th edition. Edited by Ettinger SJ, Feldman EC. Elsevier Saunders, St Louis; 2005:1492-1495.
• [2]Hall EJ, Bond PM, McLean C, Batt RM, McLean L: A survey of the diagnosis and treatment of canine exocrine pancreatic insufficiency. J Small Animal Pract 1991, 32:613-619.
• [3]Batchelor DJ, Noble PJM, Taylor RH, Cripps PJ, German AJ: Prognostic factors in canine exocrine pancreatic insufficiency: Prolonged survival is likely if clinical remission is achieved. J Vet Intern Med 2007, 21:54-60.
• [4]International Conference on Harmonisation: Good Clinical Practice. [http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html webcite]
• [5]Laflamme D: Development and validation of a body condition score system for dogs. Canine Pract 1997, 22:10-15.
• [6]Jergens AE, Schreiner CA, Frank DE, Niyo Y, Ahrens FE, Eckersall PD, Benson TJ, Evans R: A scoring index for disease activity in canine inflammatory bowel disease. J Vet Intern Med 2003, 17:291-29.
• [7]Simpson JW, Maskell IE, Quigg J, Markwell PJ: Long term management of canine exocrine pancreatic insufficiency. J Small Anim Pract 1994, 35:133-138.
• [8]O'Connor AM, Sargeant JM, Gardner IA, Dickson JS, Torrence ME, Dewey CE, Dohoo IR, Evans RB, Gray JT, Greiner M, Keefe G, Lefebvre SL, Morley PS, Ramirez A, Sischo W, Smith DR, Snedeker K, Sofos J, Ward MP, Wills R: The REFLECT statement: methods and processes of creating reporting guidelines for randomized controlled trials for livestock and food safety by modifying the CONSORT statement. Zoonoses Public Health 2010, 57:95-104.
• [9]German AJ, Morgan LE: How often do veterinarians assess the bodyweight and body condition of dogs? Vet Rec 2008, 163:503-505.
• [10]Simpson JW, Maskell IE, Quigg J, Markwell J: Long term management of canine exocrine pancreatic insufficiency. J Small AnimPract 1997, 35:133-138.
• [11]Pidgeon G: Effect of diet on exocrine pancreatic insufficiency in dogs. J Am Vet Med Assoc 1982, 181:232-235.
• [12]Suzuki A, Mizumoto A, Reknimitr R, Sarr MG, DiMango EP: Effect of bacterial or porcine lipase with low- or high-fat diets on nutrient absorption in pancreatic-insufficient dogs. Gastroenterology 1999, 116:431-437.
• [13]Biourge V, Fontaine J: Exocrine pancreatic insufficiency and adverse reaction to food in dogs: a positive response to a high-fat, soy isolate hydrolysate–based diet. J Nutr 2004, 134:2166S-2168S.
• [14]Westermarck E, Junttila JT, Wiberg M: Role of low dietary fat in the treatment of dogs with exocrine pancreatic insufficiency. Am J Vet Res 1995, 56:600-60.
• [15]Westermarck E, Wiberg M: Effects of diet on clinical signs of exocrine pancreatic insufficiency in dogs. J Am Vet Med Assoc 2006, 228:225-229.
• [16]Batchelor DJ, Noble PJM, Taylor RH, Cripps PJ, German AJ: Breed Associations for Canine Exocrine Pancreatic Insufficiency. J Vet Intern Med 2007, 21:207-214.